The Ethics of Thrombolytic Trials Beyond 3 (or 4.5) Hours: Randomized Controlled Trials Are Required to Change Clinical Practice
Stroke 40:1545, Donnan,G.A. &Davis,S.M., 2009
Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial by Stroke Subtypes
Stroke 40:1405-1409, Amarenco,P.,et al, 2009
Opportunistic Infections and Other Risks with Newer Multiple Sclerosis Therapies
Ann Neurol 65:367-377, Berger,J.R. &Houff,S., 2009
PML-IRIS in Patients with HIV Infection: Clinical Manifestations and Treatment with Steroids
Neurol 72:1458-1464,1454, Tan,K.,et al, 2009
Cost-Effectiveness of Patient Selection Using Penumbral-Based MRI for Intravenous Thrombolysis
Stroke 40:1710-1720, Earnshaw,S.R.,et al, 2009
Identifying Patients at High Risk for Poor Outcomes After Intra-Arterial Therapy for Acute Ischemic Stroke
Stroke 40:1780-1785, Hallevi,H.,et al, 2009
Fast-In, Fast-Out
Lancet 373:1398, Hefele,B.,et al, 2009
Diagnostic Value of N-methyl-D-aspartate Receptor Antibodies in Women with New-Onset Epilepsy
Arch Neurol 66:458-464, Niehusmann,P.,et al, 2009
Clinicopath Conf, Acute HIV-1 Infection
NEJM 360:1540-1548, Case 11-2009, 2009
Human Natural Autoantibodies in the Treatment of Neurologic Disease
Neurol 72:1269-1276, Rodriguez,M.,et al, 2009
Recurrent Pericarditis Due to Natalizumab Treatment
Neurol 72:1616-1617, Cohen,M.,et al, 2009
Telemedicine Versus Telephone for Remote Emergency Stroke Consultations: A Critically Appraised Topic
The Neurologist 15:163-166, Capampngan,D.J.,et al, 2009
Antivenom for Critically Ill Children with Neurotoxicity from Scorpion Stings
NEJM 360:2090-2098, Boyer,L.V.,et al, 2009
Progressive Multifocal Leukoencephalopathy and Relapsing-Remitting Multiple Sclerosis: A Comparative Study
Arch Neurol 66:593-599, Boster,A.,et al, 2009
Fomepizole for Ethylene Glycol and Methanol Poisoning
NEJM 360:2216-2223, Brent,J., 2009
Thrombolysis in Young Adults with Ischemic Stroke
Stroke 40:2085-2091, Putaala,J.,et al, 2009
Treatment of Atherosclerotic Intracranial Arterial Stenosis
Stroke 40:2257-2261, Turan,T.N.,et al, 2009
4.5 Hours: The New Time Window for Tissue Plasminogen Activator in Stroke
Stroke 40:2266-2267, Davis,S.M. &Donnan,G.A., 2009
Statin Therapy After First Stroke Reduces 10-Year Stroke Recurrence and Improves Survival
Neurol 72:1816-1822, Milionis,H.J.,et al, 2009
Clinicopath Conf, Neuro-Behcets Disease
NEJM 360:2341-2351, Case 17-2009, 2009
Parkinsonism in HIV-Infected Patients on Highly Active Antiretroviral Therapy
Neurol 73:401-403, Tisch,S. &Brew,B., 2009
Toxic and Drug-Induced Myopathies
JNNP 80:832-838, Dalakas,M.C., 2009
Expansion of the Time Window for Treatment of Acute Ischemic Stroke with Intravenous Tissue Plasminogen Activator: A Science Advisory from the American Heart Association/American Stroke Association
Stroke 40:2945-2948, del Zoppo,G.J.,et al, 2009
MR Mismatch Is Useful for Patient Selection for Thrombolysis: Yes
Stroke 40:2906-2907,2910, Fiebach,J.B. &Schellinger,P.D., 2009
Oral Fingolimod (FTY720) in Multiple Sclerosis: Two-Year Results of a Phase II Extension Study
Neurol 72:73-79, OConnor,P.,et al, 2009
Use of MRI to Estimate the Therapeutic Window in Acute Stroke: Is Perfusion-Weighted Imaging/Diffusion-Weighted Imaging Mismatch an EPITHET for Salvageable Ischemic Brain Tissue?
Stroke 40:333-335, Toth,G. &Albers,G.W., 2009
Hearing Improvement After Bevacizumab in Patients with Neurofibromatosis Type 2
NEJM 361:358-367, Plotkin,S.R.,et al, 2009
Frequency, Characteristics, and Risk Factors for Amiodarone Neurotoxicity
Arch Neurol 66:865-869, Orr,C.F. &Ahlskog,E., 2009
Intraarterial Thrombolysis Within the First Three Hours After Acute Ischemic Stroke in Selected Patients
Stroke 40:2611-2612,2615, Moonis,M., 2009
Is Intraarterial tPA Within 3 Hours the Treatment of Choice for Selected Stroke Patients? No
Stroke 40:2613-2614,2615, Lindley,R.I., 2009
Number Needed to Treat to Benefit and to Harm for Intravenous Tissue Plasminogen Activator Therapy in the 3- to 4.5-Hour Window: Joint Outcome Table Analysis of the ECASS 3 Trial
Stroke 40:2433-2437,2295, Saver,J.L.,et al, 2009
Efficacy and Safety of Tissue Plasminogen Activator 3 to 4.5 Hours After Acute Ischemic Stroke: A Metaanalysis
Stroke 40:2438-2441, Lansberg,M.G.,et al, 2009
Stroke Therapy Academic Industry Roundtable (STAIR) Recommendations for Extended Window Acute Stroke Therapy Trials
Stroke 40:2594-2600, Saver,J.L.,et al, 2009
A 70-Year-Old Woman with Shingles: Review of Herpes Zoster
JAMA 302:73-80,108, Whitley,R.J., 2009
Cyclophosphamide Therapy in Pediatric Multiple Sclerosis
Neurol 72:2076-2082,2064, Makhani,N.,et al, 2009
Primary Angiitis of the Central Nervous System
Arch Neurol 66:704-709, Birnbaum,J. &Hellmann,D.B., 2009
Anti-N-Methyl-D-Aspartate Receptor (NHMDAR) Encephalitis in Children and Adolescents
Ann Neurol 66:11-18,1, Florance,N.R.,et al, 2009
Transcranial Ultrasound in Clinical Sonothrombolysis (TUCSON) Trial
Ann Neurol 66:28-38, Molina,C.A.,et al, 2009
Statin Treatment and Stroke Outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial
Stroke 40:3526-3531,3413, Goldstein,L.,et al, 2009
Interventions in the Management of Serum Lipids for Preventing Stroke Recurrence
Stroke 40:e622-e623, Manktelow,B. &Potter,J., 2009
Point-of-Care International Normalized Ratio Testing Accelerates Thrombolysis in Patients With Acute Ischemic Stroke Using Oral Anticoagulants
Stroke 40:3547-3551, Rizos,T.,et al, 2009
Primary Central Nervous System Lymphoma in a Patient Treated with Natalizumab
Ann Neurol 66:403-406, 261, 262, Schweikert,A.,et al, 2009
Natalizumab and Central Nervous System Lymphoma: No Clear Association
Ann Neurol 66:261-262, Bozic,C.,et al, 2009
Natalizumab: A Double-Edged Sword?
Ann Neurol 66:262-263, DeAngelis,L., 2009
Intraventricular Fibrinolysis and Lumbar Drainage for Ventricular Hemorrhage
Stroke 40:3275-3280, Staykov,D.,et al, 2009
Plasmablastic Lymphoma: CNS Involvement, Coexistence of Other Malignancies, Possible Viral Etiology, and Dismal Outcome
Ann Hematol 88:351-358, Ustun, C.,et al, 2009
Reversible Extralimbic Paraneoplastic Encephalopathies with Large Abnormalities on Magnetic Resonance Images
Arch Neurol 66:268-271, McKeon,A.,et al, 2009
MRI Findings Associated With Acute Liver Failure
Neurol 72:2130-2131, Fridman,V.,et al, 2009
Safety of Biologic Agents After Rituximab Therapy in Patients With Rheumatoid Arthritis
Rheum Int: December 2009, Mishra, R.,et al, 2009
Best Practice Recommendations for the Selection and Management of Patients with Multiple Sclerosis Receiving Natalizumab Therapy
Mutliple Sclerosis 15:S26-S36, Coyle,P.K.,et al, 2009